IL6 and metabolic dysfunction-associated steatotic liver disease: Recent studies have demonstrated that myeloid-specific interleukin-6 (IL-6) signaling inhibits NAFLD-associated liver fibrosis by delivering exosomes enriched with anti-fibrotic miR-223 to hepatocytes [54].